Literature DB >> 21446649

Discovery of highly potent and neurotensin receptor 2 selective neurotensin mimetics.

Jürgen Einsiedel1, Cornelia Held, Maud Hervet, Manuel Plomer, Nuska Tschammer, Harald Hübner, Peter Gmeiner.   

Abstract

The neurotensin receptor subtype 2 (NTS2) is involved in the modulation of tonic pain sensitivity and psychiatric diseases and is, therefore, regarded as a highly attractive pharmacological target protein. Aiming to discover NTS2 selective ligands, we herein describe the identification of screening hits and the chemical synthesis of structural variants leading to the highly potent and NTS2 selective peptide-peptoid hybrids of type 3. The neurotensin mimetics 3a and 3e-g incorporating an N-(4-hydroxyphenethyl)glycine substructure exhibit single digit nanomolar affinity (K(i) = 4.3-8.8 nM) and 1900-12000 fold selectivity over the neurotensin receptor subtype 1 (NTS1). According to functional experiments, the test compounds 3a and 3e-g displayed an inhibition of constitutive mitogen-activated protein kinase (MAPK) activity exceeding 2.6-4.6 times the inverse agonist activity of the endogenous ligand neurotensin.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21446649     DOI: 10.1021/jm200006c

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  10 in total

1.  Modifications at Arg and Ile Give Neurotensin(8-13) Derivatives with High Stability and Retained NTS1 Receptor Affinity.

Authors:  Lisa Schindler; Günther Bernhardt; Max Keller
Journal:  ACS Med Chem Lett       Date:  2019-05-10       Impact factor: 4.345

2.  The amide linker in nonpeptide neurotensin receptor ligands plays a key role in calcium signaling at the neurotensin receptor type 2.

Authors:  James B Thomas; Angela M Giddings; Srinivas Olepu; Robert W Wiethe; Keith R Warner; Philippe Sarret; Jean-Michel Longpre; Scott P Runyon; Brian P Gilmour
Journal:  Bioorg Med Chem Lett       Date:  2015-04-03       Impact factor: 2.823

3.  Expanding chemical diversity of conotoxins: peptoid-peptide chimeras of the sodium channel blocker μ-KIIIA and its selenopeptide analogues.

Authors:  Aleksandra Walewska; Tiffany S Han; Min-Min Zhang; Doju Yoshikami; Grzegorz Bulaj; Krzysztof Rolka
Journal:  Eur J Med Chem       Date:  2013-05-01       Impact factor: 6.514

4.  A marine analgesic peptide, Contulakin-G, and neurotensin are distinct agonists for neurotensin receptors: uncovering structural determinants of desensitization properties.

Authors:  Hee-Kyoung Lee; Liuyin Zhang; Misty D Smith; Aleksandra Walewska; Nadeem A Vellore; Riccardo Baron; J Michael McIntosh; H Steve White; Baldomero M Olivera; Grzegorz Bulaj
Journal:  Front Pharmacol       Date:  2015-02-10       Impact factor: 5.810

5.  Identification of 1-({[1-(4-fluorophenyl)-5-(2-methoxyphenyl)-1H-pyrazol-3-yl]carbonyl}amino)cyclohexane carboxylic acid as a selective nonpeptide neurotensin receptor type 2 compound.

Authors:  James B Thomas; Angela M Giddings; Robert W Wiethe; Srinivas Olepu; Keith R Warner; Philippe Sarret; Louis Gendron; Jean-Michel Longpre; Yanan Zhang; Scott P Runyon; Brian P Gilmour
Journal:  J Med Chem       Date:  2014-06-05       Impact factor: 7.446

6.  Structure-based evolution of subtype-selective neurotensin receptor ligands.

Authors:  Carolin Schaab; Ralf Christian Kling; Jürgen Einsiedel; Harald Hübner; Tim Clark; Dieter Seebach; Peter Gmeiner
Journal:  ChemistryOpen       Date:  2014-09-23       Impact factor: 2.911

7.  Fluorescence Labeling of Neurotensin(8-13) via Arginine Residues Gives Molecular Tools with High Receptor Affinity.

Authors:  Max Keller; Shahani A Mahuroof; Vivyanne Hong Yee; Jessica Carpenter; Lisa Schindler; Timo Littmann; Andrea Pegoli; Harald Hübner; Günther Bernhardt; Peter Gmeiner; Nicholas D Holliday
Journal:  ACS Med Chem Lett       Date:  2019-11-19       Impact factor: 4.345

8.  Development of a Neurotensin-Derived 68Ga-Labeled PET Ligand with High In Vivo Stability for Imaging of NTS1 Receptor-Expressing Tumors.

Authors:  Lisa Schindler; Jutta Moosbauer; Daniel Schmidt; Thilo Spruss; Lukas Grätz; Steffen Lüdeke; Frank Hofheinz; Sebastian Meister; Bernd Echtenacher; Günther Bernhardt; Jens Pietzsch; Dirk Hellwig; Max Keller
Journal:  Cancers (Basel)       Date:  2022-10-08       Impact factor: 6.575

9.  In vivo monitoring of the antiangiogenic effect of neurotensin receptor-mediated radiotherapy by small-animal positron emission tomography: a pilot study.

Authors:  Simone Maschauer; Tina Ruckdeschel; Philipp Tripal; Roland Haubner; Jürgen Einsiedel; Harald Hübner; Peter Gmeiner; Torsten Kuwert; Olaf Prante
Journal:  Pharmaceuticals (Basel)       Date:  2014-04-16

10.  Structure-guided development of heterodimer-selective GPCR ligands.

Authors:  Harald Hübner; Tamara Schellhorn; Marie Gienger; Carolin Schaab; Jonas Kaindl; Laurin Leeb; Timothy Clark; Dorothee Möller; Peter Gmeiner
Journal:  Nat Commun       Date:  2016-07-26       Impact factor: 14.919

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.